IBDEI03W ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1290,0)
 ;;=C94.40^^3^39^7
 ;;^UTILITY(U,$J,358.3,1290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1290,1,3,0)
 ;;=3^Acute panmyelosis w myelofibrosis not achieve remission
 ;;^UTILITY(U,$J,358.3,1290,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,1290,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,1291,0)
 ;;=C94.41^^3^39^8
 ;;^UTILITY(U,$J,358.3,1291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1291,1,3,0)
 ;;=3^Acute panmyelosis w myelofibrosis, in remission
 ;;^UTILITY(U,$J,358.3,1291,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,1291,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,1292,0)
 ;;=C94.42^^3^39^9
 ;;^UTILITY(U,$J,358.3,1292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1292,1,3,0)
 ;;=3^Acute panmyelosis w myelofibrosis, in relapse
 ;;^UTILITY(U,$J,358.3,1292,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,1292,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,1293,0)
 ;;=D47.1^^3^39^27
 ;;^UTILITY(U,$J,358.3,1293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1293,1,3,0)
 ;;=3^Chronic myeloproliferative disease
 ;;^UTILITY(U,$J,358.3,1293,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,1293,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,1294,0)
 ;;=D47.9^^3^39^90
 ;;^UTILITY(U,$J,358.3,1294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1294,1,3,0)
 ;;=3^Neoplm of uncrt behav of lymphoid,hematpoetc & rel tiss,unsp
 ;;^UTILITY(U,$J,358.3,1294,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,1294,2)
 ;;=^5002260
 ;;^UTILITY(U,$J,358.3,1295,0)
 ;;=C88.0^^3^39^134
 ;;^UTILITY(U,$J,358.3,1295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1295,1,3,0)
 ;;=3^Waldenstrom macroglobulinemia
 ;;^UTILITY(U,$J,358.3,1295,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,1295,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,1296,0)
 ;;=D50.0^^3^39^41
 ;;^UTILITY(U,$J,358.3,1296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1296,1,3,0)
 ;;=3^Iron deficiency anemia secondary to blood loss (chronic)
 ;;^UTILITY(U,$J,358.3,1296,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,1296,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,1297,0)
 ;;=D50.9^^3^39^42
 ;;^UTILITY(U,$J,358.3,1297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1297,1,3,0)
 ;;=3^Iron deficiency anemia, unspecified
 ;;^UTILITY(U,$J,358.3,1297,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,1297,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,1298,0)
 ;;=D51.0^^3^39^131
 ;;^UTILITY(U,$J,358.3,1298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1298,1,3,0)
 ;;=3^Vit B12 defic anemia d/t intrinsic factor deficiency
 ;;^UTILITY(U,$J,358.3,1298,1,4,0)
 ;;=4^D51.0
 ;;^UTILITY(U,$J,358.3,1298,2)
 ;;=^5002284
 ;;^UTILITY(U,$J,358.3,1299,0)
 ;;=D51.1^^3^39^132
 ;;^UTILITY(U,$J,358.3,1299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1299,1,3,0)
 ;;=3^Vit B12 defic anemia d/t slctv vit B12 malabsorp w protein
 ;;^UTILITY(U,$J,358.3,1299,1,4,0)
 ;;=4^D51.1
 ;;^UTILITY(U,$J,358.3,1299,2)
 ;;=^5002285
 ;;^UTILITY(U,$J,358.3,1300,0)
 ;;=D53.9^^3^39^91
 ;;^UTILITY(U,$J,358.3,1300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1300,1,3,0)
 ;;=3^Nutritional anemia, unspecified
 ;;^UTILITY(U,$J,358.3,1300,1,4,0)
 ;;=4^D53.9
 ;;^UTILITY(U,$J,358.3,1300,2)
 ;;=^5002298
 ;;^UTILITY(U,$J,358.3,1301,0)
 ;;=D57.1^^3^39^128
 ;;^UTILITY(U,$J,358.3,1301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1301,1,3,0)
 ;;=3^Sickle-cell disease without crisis
 ;;^UTILITY(U,$J,358.3,1301,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,1301,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,1302,0)
 ;;=D57.00^^3^39^35
 ;;^UTILITY(U,$J,358.3,1302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1302,1,3,0)
 ;;=3^Hb-SS disease with crisis, unspecified
 ;;^UTILITY(U,$J,358.3,1302,1,4,0)
 ;;=4^D57.00
 ;;
 ;;$END ROU IBDEI03W
